Replimune stock.
View 13F filing holders of Replimune Group Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. ... *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*** Elevate your investments Try it for free. We give you the access and tools ...
Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types.Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.S-3 1 tm2027068-1_s3.htm FORM S-3 ...
REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.Replimune Group Stock Price | REPL Stock Quote, News, and History | Markets Insider The latest Replimune Group stock prices, stock quotes, news, and …
Mutual fund, Stake, Shares owned, Total value ($), Shares bought / sold, Total change. T Rowe Price New Horizons Fund, 4.14%, 2,444,774, 35,620,357, -840 ...BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.
PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Nov 29, 2023 · The Replimune Group Inc. stock price fell by -1.34% on the last day (Wednesday, 22nd Nov 2023) from $10.43 to $10.29. During the last trading day the stock fluctuated 4.10% from a day low at $10.25 to a day high of $10.67. The price has fallen in 7 of the last 10 days and is down by -10.83% for this period. REPL News. This page features the latest news about the Replimune stock. Replimune earnings missed by $0.09, revenue was in line with estimates. By Investing.com. • Nov 07, 2023. Replimune ...A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...
Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …
Also, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The stock was sold at …
1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the ...Founded Date Mar 2015. Founders Philip Sparke, Robert Coffin. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Replimune Group Inc. Stock Symbol NASDAQ:REPL. Company Type For Profit. Contact Email [email protected]. Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the …Mar 30, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...
Customizable interactive chart for Replimune Group Inc with latest real-time price quote, charts, latest news, technical analysis and opinions.Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed ...Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M.Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days.
Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ...
WOBURN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for its lead …13 Jul 2023 ... Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the ...Nov 7, 2023 · In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential. Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc. On September 12, 2023, Pamela Esposito, the Chief Business Officer of Replimune Group Inc (NASDAQ:REPL), sold 5,658 shares ...About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize …13 Jul 2023 ... Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the ...Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Aug 8, 2023 at 1:30 PM EDT. Jefferies Global Healthcare Conference. Jun 8, 2023 at 1:00 PM EDT. Piper Sandler Spring Biopharma Symposium. May 17 - May 18, 2023. Jefferies Biotech on the Bay Summit. Mar 16, 2023. Barclays Global Healthcare Conference. Mar 15, 2023 at 2:05 PM EDT.About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …
REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POST
11.32. -0.21. -1.82%. WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio ...
Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ...In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...Replimune Group Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more.A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.8 Jun 2020 ... * REPLIMUNE GROUP - PROPOSED OFFERING ALSO OF PRE-FUNDED WARRANTS TO PURCHASE SHARES OF STOCK, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS ...Nov 5, 2023 · To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ... Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.
Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m... Find the latest Replimune Group, Inc. (REPL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ... Instagram:https://instagram. best way to learn how to trade optionscrispr stock forecast 2030best time of day to trade forexnew american funding heloc reviews PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL … six month t bill ratebest stocks for october 2023 Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis. mr beast hearing aids 14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune …15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies.